CD7 CAR-T for high-risk T-cell leukemia in children
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called CD7 CAR-T for children with high-risk T-cell lymphoblastic leukemia or lymphoma who have finished initial chemotherapy and are in remission. It aims to prevent relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or younger and have just been diagnosed with high-risk T-cell leukemia or lymphoma.
- You completed the first round of chemotherapy and are in complete remission with very low cancer cells in your bone marrow.
- Your doctor considers your leukemia to be high-risk or you did not respond well to the first chemotherapy.
- You have enough lymphocytes (a type of white blood cell) and are in good overall health.
- Your heart, kidneys, and liver are working well enough, and you do not have an active serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
This trial tests a personalized therapy where your child's own immune cells are modified to find and destroy cancer cells that carry a specific marker called CD7. It is for children and young adults whose T-cell leukemia or lymphoma has come back or not responded to standard treatments.
This trial tests a special immune cell therapy (CAR-T) that targets CD7, a protein found on T-cell leukemia and lymphoma cells. It is for people who have very small amounts of cancer remaining after a stem cell transplant.
This trial tests a new treatment made from your own immune cells, designed to target and kill cancer cells that have a protein called CD7. It might help people with T-cell leukemia or lymphoma that has returned or not responded to standard treatments.
Hear when a new T Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.